Beclomethasone, formoterol and glycopyrronium: effect on an ex vivo model of COPD exacerbation Source: Virtual Congress 2020 – Scientific advances in airway pharmacology Year: 2020
Beclomethasone, formoterol and glycopyrronium: synergism of triple therapy on human airways Source: International Congress 2019 – Advances in COPD pharmacology Year: 2019
Synergistic interaction between beclomethasone diproprionate and formoterol fumarate in an ex vivo model of bronchial asthma Source: International Congress 2018 – Basic pharmacology Year: 2018
Effect of ICS/LABA combination in an ex vivo model of COPD exacerbation Source: Virtual Congress 2020 – Clinical and basic pharmacology for COPD Year: 2020
Bronchodilator effect of an inhaled combination therapy with salmeterol + fluticasone and formoterol + budesonide in patients with COPD Source: Eur Respir J 2002; 20: Suppl. 38, 386s Year: 2002
The additive effect of theophylline on a combination of formoterol and tiotropium in stable COPD Source: Eur Respir J 2006; 28: Suppl. 50, 212s Year: 2006
Efficacy of the novel inhaled corticosteroid, fluticasone furoate (FF)/long-acting beta2 -agonist, vilanterol (VI) combination in reducing COPD exacerbations Source: Annual Congress 2012 - Trials in COPD: novel treatments and insights Year: 2012
Adding glycopyrronium to beclomethasone/formoterol combination: synergistic effect on human small airways of COPD donors Source: Virtual Congress 2021 – Airway pharmacology: translational and basic science Year: 2021
Improved asthma control with budesonide/formoterol in a single inhaler, compared with budesonide alone Source: Eur Respir J 2001; 18: 262-268 Year: 2001
Beclomethasone, formoterol and glycopyrronium: ceiling effect in small airways of COPD patients Source: Virtual Congress 2020 – Advances in pharmacological treatment of COPD Year: 2020
Beclomethasone/formoterol versus budesonide/formoterol combination therapy in asthma Source: Eur Respir J 2007; 29: 682-689 Year: 2007
Formoterol (Modulite), tiotropium and their combination in patients with acute exacerbation of chronic bronchitis: preliminary data Source: Eur Respir J 2005; 26: Suppl. 49, 285s Year: 2005
Assessment of long-term effects of combined extra-fine beclomethasone and formoterol treatment in asthma patients using functional imaging Source: Annual Congress 2010 - Drug delivery and pharmacokinetics I Year: 2010
Combination therapy with maintenance budesonide and formoterol in COPD Source: Eur Respir J 2004; 24: 1070 Year: 2004
Free triple combination of glycopyrronium, indacaterol and ICS improves lung function and dyspnoea versus free double combination of indacaterol and ICS in patients with COPD: A post-hoc analysis from the GLOW6 study Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014
Anti-inflammatory effect and clinical efficacy of concomitant treatments to steroid inhaler in bronchial asthma: montelukast versus salmeterol Source: Eur Respir J 2006; 28: Suppl. 50, 315s Year: 2006
Effects of budesonide/formoterol combination therapy versus budesonide on airway dimensions in asthma Source: Annual Congress 2012 - Clinical aspects and treatment of asthma and allergic respiratory diseases Year: 2012
Comparison of a combination of tiotropium and formoterol to salmeterol and fluticasone in moderate COPD Source: Eur Respir J 2005; 26: Suppl. 49, 14s Year: 2005
Improved asthma control with budesonide/formoterol via a single inhaler, compared with budesonide alone, in moderate persistent asthma Source: Eur Respir J 2001; 18: Suppl. 33, 48s Year: 2001
Budesonide and formoterol in mild persistent asthma compared with doubling the dose of budesonide - a cost-effectiveness analysis Source: Eur Respir J 2001; 18: Suppl. 33, 517s Year: 2001